We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2024
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Balancing Mitochondrial Division Critical in Treating Huntington's Disease

By LabMedica International staff writers
Posted on 09 Mar 2011
Reducing the activity of an enzyme critical to mitochondrial division reduces damage caused by mutant huntingtin proteins and slows the development of symptoms of Huntington's disease.

Huntington's disease is a neurodegenerative disorder caused by a mutation in the gene that encodes the huntingtin (Htt) protein. The mutated gene adds from one to many dozens of extra glutamine molecules to Htt. Incomplete breakdown of the enlarged protein results in the buildup of toxic, misfolded peptides that destroy cells in the nervous system. The mechanisms of mutant huntingtin-mediated neurotoxicity have been unclear; however, mitochondrial dysfunction is a key event in Huntington's disease pathogenesis.

Investigators at the University of Central Florida (Orlando, USA) showed in a study published in the February 20, 2011, online edition of the journal Nature Medicine that mutant huntingtin triggered mitochondrial fragmentation in rat neurons and in fibroblasts of individuals with Huntington's disease in vitro, and in a mouse model of Huntington's disease in vivo, before the appearance of neurological defects and huntingtin aggregates.

Mutant huntingtin abnormally interacted with the mitochondrial fission GTPase dynamin-related protein-1 (DRP1) in mice and humans with Huntington's disease, which, in turn, stimulated its enzymatic activity. Dynamin-1 is a member of the dynamin subfamily of GTP-binding proteins. This protein possesses unique mechanochemical properties used to tubulate and sever membranes, and is involved in clathrin-mediated endocytosis and other vesicular trafficking processes.

Mutant huntingtin–mediated mitochondrial fragmentation, mitochondrial transport, and neuronal cell death were all reversed by reducing DRP1 GTPase activity.

"Mitochondria require balanced cycles of division and fusion to maintain their ability to produce energy," said senior author Dr. Ella Bossy-Wetzel, professor of biomedical sciences at the University of Central Florida. "The protein DRP1 is needed for mitochondrial division. We found that in Huntington's disease, DRP1 becomes overactive and causes too much mitochondrial division without balancing fusion.”

"The next step will be to test the DRP1 function in animals and patients to see whether the protein also protects the brain,” said Dr. Bossy-Wetzel. "This could be done before the onset of disease in patients who have the mutant Huntington gene, but have no neurological symptoms. The hope is that we might be able to delay the onset of disease by improving the energy metabolism of the brain.”

Related Links:
University of Central Florida



New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Automated Blood Typing System
IH-500 NEXT
New
Progesterone Serum Assay
Progesterone ELISA Kit
New
Silver Member
Static Concentrator
BJP 10

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries